1 withdrawn. 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 1 | Withdrawn 1 |
Follow this drug Literature Review of Transferrin Receptor-Targeted Liposomal p53 cDNA trials Research Report on Transferrin Receptor-Targeted Liposomal p53 cDNA
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| SGT-53, Carboplatin, and Pembrolizumab for the Treatment of Metastatic Triple Negative Inflammatory Breast Cancer Carboplatin, Pembrolizumab, Transferrin Receptor-Targeted Liposomal p53 cDNA - Anatomic Stage IV Breast Cancer AJCC v8, Breast Inflammatory Carcinoma | Phase 1 | Withdrawn | Northwestern University | 2022-11-10 | 2022-11-15 |
Inflammatory Breast Neoplasms (1) · Triple Negative Breast Neoplasms (1)
United States (1)
Massimo Cristofanilli, MD, FACP (1)
P30CA060553 (1)